Skip to content
10-Q

Quarterly Report

ACRO BIOMEDICAL CO., LTD. ACBM

0001640334-25-001169

← back to feed
Filed
Jul 11, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2023 · Jul 11, 2025 60.04M sh
Current Liabilities Q3 2023 · Sep 30, 2023 $258.64K
Current Liabilities Q3 2023 · Dec 31, 2022 $201.12K
Total Liabilities Q3 2023 · Sep 30, 2023 $258.64K
Total Liabilities Q3 2023 · Dec 31, 2022 $201.12K
Current Assets Q3 2023 · Sep 30, 2023 $12.5K
Current Assets Q3 2023 · Dec 31, 2022 $657.54K
Total Assets Q3 2023 · Sep 30, 2023 $19.03K
Total Assets Q3 2023 · Dec 31, 2022 $687.49K
Gross Profit Q3 2023 · Sep 30, 2023 $0
Gross Profit Q3 2023 · Sep 30, 2023 $0
Gross Profit Q3 2023 · Sep 30, 2022 $0
Gross Profit Q3 2023 · Sep 30, 2022 $76.5K
Cost Of Revenue Q3 2023 · Sep 30, 2023 $0
Cost Of Revenue Q3 2023 · Sep 30, 2023 $0
Cost Of Revenue Q3 2023 · Sep 30, 2022 $0
Cost Of Revenue Q3 2023 · Sep 30, 2022 $222K
Shares Diluted Q3 2023 · Sep 30, 2022 60.04M sh
Shares Diluted Q3 2023 · Sep 30, 2022 60.04M sh
Operating Cash Flow Q3 2023 · Sep 30, 2022 −$136.91K
Stockholders Equity Q3 2023 · Sep 30, 2022 $492.16K
Stockholders Equity Q3 2023 · Jun 30, 2022 $574.89K
Stockholders Equity Q3 2023 · Mar 31, 2022 $643.22K
Stockholders Equity Q3 2023 · Dec 31, 2021 $643.71K
Eps Diluted Q3 2023 · Sep 30, 2022 −$0.07
Eps Diluted Q3 2023 · Sep 30, 2022 −$0.20
Sga Expense Q3 2023 · Sep 30, 2022 $1.49M
Sga Expense Q3 2023 · Sep 30, 2022 $4.45M
Rd Expense Q3 2023 · Sep 30, 2022 $2.52M
Rd Expense Q3 2023 · Sep 30, 2022 $7.56M
Net Income Q3 2023 · Sep 30, 2022 −$4.01M
Net Income Q3 2023 · Sep 30, 2022 −$11.94M
Net Income Q3 2023 · Jun 30, 2022 −$4M
Net Income Q3 2023 · Mar 31, 2022 −$3.93M
Operating Income Q3 2023 · Sep 30, 2022 −$4.01M
Operating Income Q3 2023 · Sep 30, 2022 −$11.94M
Revenue Q3 2023 · Sep 30, 2022 $0
Revenue Q3 2023 · Sep 30, 2022 $298.5K